Quantcast

Latest Hyperuricemia Stories

2009-12-01 07:00:00

SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced positive results from the first dosing group of an ongoing drug-drug interaction and pharmacodynamic study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, and febuxostat (Uloric®, Takeda Pharmaceutical Company Limited; Adenuric®, Ipsen). This randomized, placebo-controlled study in normal healthy volunteers with baseline...

2009-11-06 07:00:00

SAN DIEGO, Nov. 6 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), today reported recent accomplishments and financial results for the third quarter and nine months ended September 30, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20091104/ARDEALOGO) "Since our last quarterly update, we have confirmed the...

2009-10-19 12:44:50

Additional analysis showed that reduction and long-term maintenance of normal serum urate levels also reduced risk of future gout flares Data presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology highlight effects of baseline characteristics on achievement of serum uric acid (sUA) levels to <6.0 mg/dL and the frequency of flares with ULORIC® (febuxostat) treatment. A subset of subjects from the CONFIRMS trial who received prior...

2009-10-17 16:00:00

PHILADELPHIA, Oct. 17 /PRNewswire/ -- Data presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology highlight effects of baseline characteristics on achievement of serum uric acid (sUA) levels to <6.0 mg/dL and the frequency of flares with ULORIC® (febuxostat) treatment. A subset of subjects from the CONFIRMS trial who received prior urate-lowering therapy for up to five years achieved sUA <6.0 mg/dL more often, and had a lower...

2009-10-16 16:31:00

BRIDGEWATER, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek® (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid....

2009-09-28 08:45:00

BIRMINGHAM, Ala., Sept. 28 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it is initiating a Phase 2 study of BCX4208 for the treatment of gout. The primary objective of BioCryst's Phase 2 study is to determine the effect of different doses of orally administered BCX4208 on serum uric acid levels in patients with gout. The gout trial is expected to enroll up to 120 subjects. "Over the last few decades gout has markedly increased in...

2009-05-22 08:00:00

New Findings Released on the Third Annual Gout Awareness Day (May 22) NEW YORK, May 22 /PRNewswire/ -- The Gout & Uric Acid Education Society announced today that new survey results reveal alarming gaps in the public's awareness of gout, a painful and potentially debilitating form of arthritis that affects three to five million Americans. In a survey of more than 2,000 Americans, 65% of adults admitted to being "not at all knowledgeable" about gout and just over 70% did not know that...

2009-03-12 13:57:00

First new treatment option in 40 years for chronic management of condition DEERFIELD, Ill., March 12 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. announced today that ULORIC(R) (febuxostat) is now available by prescription in pharmacies across the United States for the chronic management of hyperuricemia in patients with gout. Gout is a chronic condition that affects more than five million Americans. This once-daily oral medication, available in 40-mg and 80-mg tablets, is the...

2009-02-13 19:29:00

First new treatment option in more than 40 years, marking second FDA approval for Takeda within one month DEERFIELD, Ill., and OSAKA, Japan, Feb. 13 /PRNewswire/ -- Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced today that the United States Food and Drug Administration (FDA) has approved ULORIC(R) (febuxostat) 40 mg and 80 mg for the chronic management of hyperuricemia in patients with gout. This once-daily, oral...

2008-12-06 11:00:00

- Results Presented at ASH Annual Meeting - SAN FRANCISCO, Dec. 6 /PRNewswire-FirstCall/ -- Sanofi-aventis today announced results of a randomized phase III study presented at the 50th Annual Meeting of the American Society of Hematology. The study in adult patients with hematological malignancies at high or potential risk for tumor lysis syndrome (TLS) demonstrated that Elitek(R) (rasburicase) significantly reduced plasma uric acid (PUA) levels compared to allopurinol alone (p=0.0012). The...


Latest Hyperuricemia Reference Libraries

45_cf9ebc73b3f1a13d4b11b52db1780092
2008-05-22 12:47:07

The Dalmatian is a coach dog which is easily recognized for its unique spotted coat. This ancient breed has been used as a guard dog, bird dog, trail hound, retriever, and most importantly a coach or carriage dog. The Dalmatian was once used to run in attendance on a coach. This ability was eventually transferred to its career as a firehouse dog. The Dalmatian once ran in front of horse-drawn fire carts to help clear a path for them as well as guide them to fires. The Dalmatian is a...

More Articles (1 articles) »
Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.